|1.||Gescher, Andreas J: 3 articles (07/2008 - 05/2006)|
|2.||Steward, William P: 3 articles (07/2008 - 05/2006)|
|3.||Verschoyle, Richard D: 2 articles (07/2008 - 04/2008)|
|4.||Brown, Karen: 2 articles (07/2008 - 04/2008)|
|5.||Messner, Donald J: 1 article (09/2008)|
|6.||Berger, Jose: 1 article (09/2008)|
|7.||Kowdley, Kris V: 1 article (09/2008)|
|8.||Schildt, Sandra: 1 article (09/2008)|
|9.||Nelson, James E: 1 article (09/2008)|
|10.||Standish, Leanna J: 1 article (09/2008)|
|1.||Ovarian Neoplasms (Ovarian Cancer)
11/01/2003 - "A phase II, non-randomised clinical study is now ongoing in our Institute aimed at evaluating the efficacy of daily administrations of IdB 1016 in the serological recurrence of ovarian cancer."
11/01/2003 - "In conclusion, these findings suggest IdB 1016 is a good candidate, with a relevant clinical potential, for use in the management of recurrent ovarian cancer. "
11/01/2003 - "Female nude mice bearing human ovarian cancer xenografts (A2780) received 450 mg/kg/day IdB 1016 daily by oral gavage until the end of the study. "
11/01/2003 - "Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer."
11/01/2003 - "This study aimed to assess, in an in vivo experimental model, the growth inhibitory effects of IdB 1016 (Silipide, a complex of silybin/phosphatidylcholine) when used as a single agent against human ovarian cancer. "
04/01/2008 - "Intervention with silipide reduced the size of well differentiated TRAMP adenocarcinomas by 31%. "
05/01/2006 - "Patients with confirmed colorectal adenocarcinoma received silibinin formulated with phosphatidylcholine (silipide) at dosages of 360, 720, or 1,440 mg silibinin daily for 7 days. "
07/01/2008 - "We tested the hypothesis that consumption of silibinin or silipide, a silibinin formulation with pharmaceutical properties superior to the unformulated agent, affect breast cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma mouse model. "
03/01/2007 - "The effect of IdB 1016 might be related to the down-regulation of HER-2/neu expression and the induction of senescent-like growth arrest and apoptosis through a p53-mediated pathway in tumor cells."
03/01/2007 - "The results show the antitumor effect of IdB 1016 in the development of spontaneous mammary tumors in HER-2/neu transgenic mice. "
03/01/2007 - "The administration of IdB 1016 delayed the development of spontaneous mammary tumors, reduced the number and size of mammary tumor masses, and diminished lung metastasization in HER-2/neu transgenic mice. "
03/01/2007 - "The mechanisms involved in the antitumor effect of IdB 1016 were evaluated by studying the apoptosis, senescent-like growth arrest, intratumoral leukocyte infiltrate, and the expression of HER-2/neu and p53 in tumoral mammary glands from transgenic mice and in human breast SKBR3 tumor cells. "
07/01/2008 - "Mice received silibinin or silipide (0.2% silibinin equivalents) with their diet from weaning, and tumour development was monitored by weekly palpation and the number and weight of neoplasms at the end of the experiment. "
|5.||Chronic Hepatitis C
|6.||Tumor Viral Antigens (Large T Antigen)
|7.||Ethanol (Ethyl Alcohol)
|1.||Heterologous Transplantation (Xenotransplantation)